$CLDX
Celldex Therapeutics, Inc.

2011 Q4 Form 10-Q Financial Statement

#000110465911060466 Filed on November 03, 2011

View on sec.gov

Income Statement

Concept 2011 Q4 2011 Q3 2010 Q3
Revenue $2.433M $2.363M $2.408M
YoY Change -93.55% -1.87% -40.25%
Cost Of Revenue $2.360M $2.320M $1.220M
YoY Change -65.29% 90.16% -41.06%
Gross Profit $80.00K $50.00K $1.190M
YoY Change -99.74% -95.8% -39.29%
Gross Profit Margin 3.29% 2.12% 49.42%
Selling, General & Admin $2.290M $2.270M $2.420M
YoY Change -9.49% -6.2% -37.14%
% of Gross Profit 2862.5% 4540.0% 203.36%
Research & Development $9.820M $8.594M $7.215M
YoY Change 45.7% 19.11% 39.56%
% of Gross Profit 12275.0% 17188.0% 606.3%
Depreciation & Amortization $840.0K $1.220M $1.060M
YoY Change -16.83% 15.09% 47.22%
% of Gross Profit 1050.0% 2440.0% 89.08%
Operating Expenses $12.46M $8.594M $7.215M
YoY Change 27.14% 19.11% -20.89%
Operating Profit -$12.38M -$11.48M -$8.879M
YoY Change -158.62% 29.27% 24.01%
Interest Expense -$350.0K $438.0K $332.0K
YoY Change -122.73% 31.93% -1760.0%
% of Operating Profit
Other Income/Expense, Net $144.0K $124.0K
YoY Change 16.13%
Pretax Income -$12.73M -$11.77M -$9.090M
YoY Change -156.18% 29.48% 26.78%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.73M -$11.77M -$9.090M
YoY Change -156.18% 29.48% 26.78%
Net Earnings / Revenue -523.22% -498.1% -377.49%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.215M -$4.003M -$4.268M
COMMON SHARES
Basic Shares Outstanding 44.15M shares 31.92M shares
Diluted Shares Outstanding 31.92M shares

Balance Sheet

Concept 2011 Q4 2011 Q3 2010 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.31M $62.80M $57.70M
YoY Change -12.75% 8.84% 121.92%
Cash & Equivalents $11.90M $13.10M $9.828M
Short-Term Investments $41.41M $49.70M $47.80M
Other Short-Term Assets $1.200M $1.400M $1.100M
YoY Change -20.0% 27.27% 22.22%
Inventory
Prepaid Expenses
Receivables $200.0K $200.0K $500.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $54.68M $64.38M $59.20M
YoY Change -13.13% 8.75% 111.43%
LONG-TERM ASSETS
Property, Plant & Equipment $9.093M $9.500M $10.90M
YoY Change -16.05% -12.84% -9.17%
Goodwill $8.965M
YoY Change 0.0%
Intangibles $24.92M
YoY Change -7.13%
Long-Term Investments
YoY Change
Other Assets $329.0K $300.0K $5.400M
YoY Change -9.37% -94.44% -11.48%
Total Long-Term Assets $43.31M $44.07M $52.60M
YoY Change -7.84% -16.22% 161.69%
TOTAL ASSETS
Total Short-Term Assets $54.68M $64.38M $59.20M
Total Long-Term Assets $43.31M $44.07M $52.60M
Total Assets $97.99M $108.4M $111.8M
YoY Change -10.87% -3.0% 132.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $935.0K $500.0K $700.0K
YoY Change 0.43% -28.57% -41.67%
Accrued Expenses $7.008M $6.000M $4.200M
YoY Change 41.98% 42.86% -4.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.100M $4.100M $12.20M
YoY Change -54.81% -66.39%
Total Short-Term Liabilities $14.30M $10.78M $23.30M
YoY Change -29.25% -53.74% 65.25%
LONG-TERM LIABILITIES
Long-Term Debt $9.000M $11.00M $0.00
YoY Change 1.12%
Other Long-Term Liabilities $5.966M $6.000M $36.50M
YoY Change 6.71% -83.56% 0.83%
Total Long-Term Liabilities $5.966M $17.00M $36.50M
YoY Change 6.71% -53.42% 0.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.30M $10.78M $23.30M
Total Long-Term Liabilities $5.966M $17.00M $36.50M
Total Liabilities $29.27M $27.77M $59.80M
YoY Change -15.61% -53.56% 18.89%
SHAREHOLDERS EQUITY
Retained Earnings -$205.0M
YoY Change 27.96%
Common Stock $271.1M
YoY Change 16.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.72M $80.67M $52.00M
YoY Change
Total Liabilities & Shareholders Equity $97.99M $108.4M $111.8M
YoY Change -10.87% -3.0% 132.43%

Cashflow Statement

Concept 2011 Q4 2011 Q3 2010 Q3
OPERATING ACTIVITIES
Net Income -$12.73M -$11.77M -$9.090M
YoY Change -156.18% 29.48% 26.78%
Depreciation, Depletion And Amortization $840.0K $1.220M $1.060M
YoY Change -16.83% 15.09% 47.22%
Cash From Operating Activities -$9.370M -$8.060M -$7.740M
YoY Change 55.91% 4.13% 40.47%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$120.0K -$530.0K
YoY Change -75.0% -77.36% 381.82%
Acquisitions
YoY Change
Other Investing Activities $8.150M $10.47M $2.610M
YoY Change 2.52% 301.15%
Cash From Investing Activities $8.040M $10.35M $2.080M
YoY Change 7.06% 397.6% -1833.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 120.0K -20.00K 340.0K
YoY Change -98.8% -105.88% -1233.33%
NET CHANGE
Cash From Operating Activities -9.370M -8.060M -7.740M
Cash From Investing Activities 8.040M 10.35M 2.080M
Cash From Financing Activities 120.0K -20.00K 340.0K
Net Change In Cash -1.210M 2.270M -5.320M
YoY Change -110.56% -142.67% -6.01%
FREE CASH FLOW
Cash From Operating Activities -$9.370M -$8.060M -$7.740M
Capital Expenditures -$110.0K -$120.0K -$530.0K
Free Cash Flow -$9.260M -$7.940M -$7.210M
YoY Change 66.25% 10.12% 33.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2660000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
50000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7848000 USD
us-gaap Royalty Expense
RoyaltyExpense
5277000 USD
CY2010Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
75255000 USD
CY2010Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160207000 USD
CY2010Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2751000 USD
CY2010Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
232679000 USD
CY2010Q4 us-gaap Common Stock Value
CommonStockValue
32000 USD
CY2010Q4 us-gaap Liabilities
Liabilities
34688000 USD
CY2010Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5591000 USD
CY2010Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
8889000 USD
CY2010Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20208000 USD
CY2010Q3 us-gaap Royalty Expense
RoyaltyExpense
1218000 USD
CY2010Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7215000 USD
CY2010Q3 us-gaap Revenues
Revenues
2408000 USD
CY2010Q3 us-gaap Royalty Revenue
RoyaltyRevenue
1037000 USD
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11772000 USD
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
13841000 USD
CY2010Q4 us-gaap Convertible Subordinated Debt Current
ConvertibleSubordinatedDebtCurrent
12412000 USD
CY2011Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2010Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
1111000 USD
CY2010Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
818000 USD
CY2010Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4936000 USD
CY2010Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
931000 USD
CY2010Q4 us-gaap Assets
Assets
109943000 USD
CY2010Q4 us-gaap Goodwill
Goodwill
8965000 USD
CY2010Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
363000 USD
CY2010Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26836000 USD
CY2010Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10832000 USD
CY2010Q4 us-gaap Assets Current
AssetsCurrent
62947000 USD
CY2010Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2010Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1525000 USD
CY2010Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
324000 USD
CY2010Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
39811000 USD
CY2011Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108448000 USD
CY2011Q3 us-gaap Stockholders Equity
StockholdersEquity
80674000 USD
CY2011Q3 us-gaap Liabilities
Liabilities
27774000 USD
CY2011Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10778000 USD
CY2011Q3 us-gaap Assets
Assets
108448000 USD
CY2011Q3 us-gaap Assets Current
AssetsCurrent
64382000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21287000 USD
CY2011Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2010Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2010Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2010Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32055382 shares
CY2010Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32055382 shares
CY2010Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000 shares
CY2011Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44147214 shares
CY2011Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44147214 shares
CY2011Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000 shares
CY2010Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2011Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000 shares
CY2010Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109943000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20908000 USD
us-gaap Revenues
Revenues
9072000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
4735000 USD
cldx Revenue From Contracts And Grants
RevenueFromContractsAndGrants
220000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32067000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-31016000 USD
us-gaap Costs And Expenses
CostsAndExpenses
37847000 USD
us-gaap Revenues
Revenues
6831000 USD
CY2010Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9087000 USD
CY2010Q3 us-gaap Interest Expense
InterestExpense
332000 USD
CY2010Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
124000 USD
CY2010Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8879000 USD
CY2010Q3 us-gaap Costs And Expenses
CostsAndExpenses
11287000 USD
CY2010Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
483000 USD
CY2010Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
50000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11478000 USD
CY2010Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31922000 shares
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25194000 USD
us-gaap Interest Expense
InterestExpense
1002000 USD
CY2010Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2421000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3379000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27571000 USD
us-gaap Costs And Expenses
CostsAndExpenses
36643000 USD
us-gaap Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
145000 USD
CY2011Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44147214 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2011
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1001000 USD
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2011-09-30
dei Document Type
DocumentType
10-Q
CY2011Q3 us-gaap Revenues
Revenues
2363000 USD
cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
4117000 USD
dei Entity Central Index Key
EntityCentralIndexKey
0000744218
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-23674000 USD
dei Entity Registrant Name
EntityRegistrantName
Celldex Therapeutics, Inc.
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
50000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1662000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
52272000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30210000 USD
CY2010Q3 cldx Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
1371000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2010Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31812000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31812000 shares
CY2010Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31922000 shares
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10199000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24357000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">(1)&nbsp; Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The accompanying unaudited condensed consolidated financial statements have been prepared by Celldex Therapeutics,&nbsp;Inc. (the &#147;Company&#148; or &#147;Celldex&#148;) in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">These interim financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and should be read in conjunction with the audited financial statements for the year ended December&nbsp;31, 2010, which are included in the Company&#146;s Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission (&#147;SEC&#148;) on March&nbsp;9, 2011.&nbsp; In the opinion of management, the interim financial statements reflect all normal recurring adjustments necessary to fairly state the Company&#146;s financial position and results of operations for the interim periods presented.&nbsp; The year-end consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future interim period or the fiscal year ending December&nbsp;31, 2011.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">At September&nbsp;30, 2011, the Company had cash, cash equivalents and marketable securities of $62.8 million; working capital of $53.6&nbsp;million; and a Term Loan balance of $15.1&nbsp;million. The Company incurred a loss of $32.1&nbsp;million for the nine months ended September&nbsp;30, 2011.&nbsp; Net cash used in operations for the nine months ended September&nbsp;30, 2011 was $26.3&nbsp;million. The Company believes that the cash, cash equivalents and marketable securities at September&nbsp;30, 2011 in addition to interest income on invested funds and the Company&#146;s ability to control certain costs, including those related to clinical trials, manufacturing and preclinical activities, will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company raised net proceeds of $35.9 million from the sale of its common stock during the nine months ended September&nbsp;30, 2011.&nbsp; During the next twelve months, the Company expects to take further steps to raise additional capital to meet its long-term liquidity needs including, but not limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company&#146;s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company&#146;s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company&#146;s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company&#146;s economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, or sell all or part of the Company.</font></p></td></tr></table>
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1663000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3406000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2141000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-554000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
108000 USD
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-88000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
546000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2197000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
11000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-22000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
89000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2188000 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13097000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-8190000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
28305000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26288000 USD
CY2010Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9828000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57002000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-47174000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
856000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-8000 USD

Files In Submission

Name View Source Status
0001104659-11-060466-index-headers.html Edgar Link pending
0001104659-11-060466-index.html Edgar Link pending
0001104659-11-060466.txt Edgar Link pending
0001104659-11-060466-xbrl.zip Edgar Link pending
a11-25795_110q.htm Edgar Link pending
a11-25795_1ex10d2.htm Edgar Link pending
a11-25795_1ex10d3.htm Edgar Link pending
a11-25795_1ex31d1.htm Edgar Link pending
a11-25795_1ex31d2.htm Edgar Link pending
a11-25795_1ex32d1.htm Edgar Link pending
cldx-20110930.xml Edgar Link completed
cldx-20110930.xsd Edgar Link pending
cldx-20110930_cal.xml Edgar Link unprocessable
cldx-20110930_def.xml Edgar Link unprocessable
cldx-20110930_lab.xml Edgar Link unprocessable
cldx-20110930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending